It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.



Vince Russell, Appointed Respiratory Discovery Director
Jim Regan, 29 February 2016

We are very happy to announce the appointment of Vince Russell as Respiratory Discovery Director at Aptuit. Vince joins us with more than 26 years of experience in pharma, biotech and CRO drug discovery in the respiratory disease area. Most recently Vince spent six years as part of Argenta's senior management team. In this time he was...

Aptuit and Icagen agree to strategic alliance
Jim Regan, 22 February 2016

Alliance to Provide Drug Discovery Customers Access to Industry Leading Ion Channel and Transporter Technologies Greenwich, CT, February 22nd, 2016 - Aptuit LLC and Icagen, Inc. today announced a strategic alliance to give drug discovery customers access to ion channel and transporter technologies and expert services.Aptuit LLC, a premier global...

Mario Maio, Appointed Global Head of CMC
Jim Regan, 17 February 2016

We are very happy to announce the appointment of Mario Maio as Global Head of CMC at Aptuit. Mario joins us after many years of R&D, and management & strategic experience in large pharmaceutical companies such as Roche, Merck, and Janssen. His career to date has seen him spend time in Italy, Germany and Switzerland.


Other announcements


The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard